News

TranS1® recognized as a leading innovator in Colorado

Tuesday, November 22, 2016

Denver-based medical device company received accolades from three top business organizations for its 2016 accomplishments 

VetDC Files Final TANOVEA™ FDA Submission for Use in Canine Lymphoma

Thursday, November 17, 2016

FORT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., a veterinary cancer therapeutics company, today announced that the Company has completed all required major and minor technical sections for Tanovea™ (rabacfosadine for injection) and filed its administrative New Animal Drug Application (NADA) for conditional approval with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM). 

Symbios Announces Two National Institutes of Health SBIR Phase I Awards for Plasma Oxidation Technology

Thursday, November 17, 2016

Symbios Technologies, Inc., a world-leading developer of dynamic aqueous plasma technology platforms, announced today that the National Cancer Institute (NCI) and the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) have awarded the company Small Business Innovation Research (SBIR) Phase I grants totaling $449,931. The funds will be used to develop innovative uses of plasma technology to create safer, more effective chemotherapeutic solutions for difficult to treat cancers, such as pancreatic cancer, and anti-infective products for the treatment of a wide range of microbial contaminants associated with hospital acquired infections (HAI) and wound recovery. 

Surefire Medical Receives Grant to Pursue Phase 1b Clinical Trial of CAR-T Immunotherapy Delivery through Precision Infusion System

Tuesday, November 15, 2016

Surefire to Collaborate with Roger Williams Medical Center and University of Colorado School of Medicine
 

CSU receives largest donation in school history

Tuesday, November 15, 2016

Colorado State University received the largest donation in school history Tuesday when Walter Scott Jr. gave the school $53.3 million. 

ARCA Biopharma: 125th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation

Monday, November 14, 2016

WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 30, 2016, and provided a business update. 

$1.1 million grant funds CU Boulder research into next-generation vaccines

Tuesday, November 08, 2016

The University of Colorado Boulder has received a $1.1 million grant from the Bill & Melinda Gates Foundation to develop next-generation vaccines that require no refrigeration and defend against infectious diseases with just one shot. 

Colorado BioScience Association Celebrates Year of Medical and Business Breakthroughs at Annual Awards Dinner

Monday, November 07, 2016

Silvergate Pharmaceuticals Named Company of the Year, BiO2 Medical Honored as Rising Star  

MIGHTY OAK MEDICAL RECEIVES SECOND FDA CLEARANCE FOR PATIENT-SPECIFIC 3D PRINTED FIREFLY® PEDICLE SCREW NAVIGATION GUIDES

Monday, November 07, 2016

New Clearance Extends Compatibility to Essentially All Currently Cleared Pedicle Screw Systems  

StartUp Health Partners with Janssen on Three Year Health Innovation Program

Wednesday, November 02, 2016

The Health Innovation Program Connects StartUp Health’s Global Army of Health Transformers, Startup Insights and Emerging Tech Solutions with Janssen’s Healthcare Leadership